COL6A1/COL6A2/COL6A3 Recombinant Monoclonal Antibody

Collagen type VI is a distinctive microfibrillar collagen that plays essential roles in maintaining extracellular matrix integrity across diverse tissues. Composed of three alpha chains—COL6A1, COL6A2, and COL6A3—this heterotrimeric protein forms beaded microfilaments that anchor basement membranes to underlying connective tissue. Collagen VI has garnered significant research attention due to its involvement in muscular dystrophies, particularly Bethlem myopathy and Ullrich congenital muscular dystrophy, as well as its emerging roles in tumor microenvironment remodeling and fibrotic disease progression.

This recombinant rabbit monoclonal antibody, clone 15C5, offers researchers the reproducibility advantages inherent to recombinant technology. Because the antibody sequence is defined and produced under controlled conditions, you can expect consistent performance across experiments and between lot numbers—a critical consideration for longitudinal studies or multi-site collaborations investigating collagen VI biology.

The antibody has been validated for immunohistochemistry and flow cytometry applications in human samples. IHC testing demonstrates clear detection in paraffin-embedded human tonsil tissue and endometrial cancer sections using citrate buffer antigen retrieval at 1:100 dilution, revealing the expected stromal and extracellular matrix staining patterns. Flow cytometry validation in 786-O renal carcinoma cells confirms intracellular detection capability, with distinct positive population shifts observed following fixation and permeabilization.

This antibody serves researchers investigating connective tissue disorders, cancer-associated matrix remodeling, and fibrosis mechanisms. Its ability to recognize epitopes shared across the collagen VI alpha chain family makes it particularly useful for studies examining overall collagen VI expression and distribution in both normal and pathological human tissues.